Literature DB >> 3479028

Use of the enzyme-linked immunoadsorbent assay to monitor the purification of glycosphingolipid antigens by high-performance liquid chromatography.

J Buehler1, U Galili, B A Macher.   

Abstract

An enzyme-linked immunoadsorbent assay (ELISA) technique has been applied to the analysis of glycosphingolipid fractions separated by high-performance liquid chromatography. Nanogram amounts of selected fractions were placed in microtiter wells and analyzed for glycosphingolipids carrying carbohydrate epitopes recognized by monoclonal antibodies using an avidin-biotin enzyme system (ABC reagents). A large number of fractions (more than 100) can be conveniently evaluated for the presence of glycosphingolipids recognized by one or more monoclonal antibodies in a single analysis. This method is a rapid and sensitive procedure for monitoring the purification of glycosphingolipid antigens and can be used in conjunction with immunostaining of glycosphingolipids separated by thin-layer chromatography.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3479028     DOI: 10.1016/0003-2697(87)90527-6

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  3 in total

1.  Structural characterization of blood group A glycosphingolipids recognized by the antibody 3G9-A.

Authors:  J B Briggs; R Mandrell; B A Macher
Journal:  Glycoconj J       Date:  1996-06       Impact factor: 2.916

Review 2.  The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance.

Authors:  Bruce A Macher; Uri Galili
Journal:  Biochim Biophys Acta       Date:  2007-11-22

3.  Lipooligosaccharides (LOS) of Neisseria gonorrhoeae and Neisseria meningitidis have components that are immunochemically similar to precursors of human blood group antigens. Carbohydrate sequence specificity of the mouse monoclonal antibodies that recognize crossreacting antigens on LOS and human erythrocytes.

Authors:  R E Mandrell; J M Griffiss; B A Macher
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.